Fosun on a Growth Path: Innovation and Globalization as Keys to Success

Fosun, a globally active company, is increasingly relying on its innovative capacity to ensure future growth. Guo Guangchang, Executive Director and Chairman, emphasized the importance of platforms like Fosun Pharma to specifically address customer needs. Despite the sale of assets, the company remains strategically focused on investments in areas such as CAR-T technology and surgical robots. Globalization plays a central role in this, not least through increased research and development activities and sales in the USA. An important step in Fosun's corporate strategy is the optimization of the portfolio through the sale of non-core assets. Wang Qunbin, Executive Director and Co-Chairman, explained that the company aims to reduce its liabilities to around 60 billion RMB over the next three years. The goal is to raise the credit rating to investment-grade level and provide added value to shareholders through targeted divestitures and asset management. Fosun's international expansion strategy is already showing success: Operating in over 35 countries, half of the workforce comes from abroad. Chen Qiyu, Executive Director and Co-CEO, emphasized the importance of global research and business development. Particularly noteworthy is the synergy between Fosun's insurance activities in Portugal and local health and financial institutions that support international growth. Fosun's "asset-light" strategy, explained by Wang Qunbin, focuses on partnership collaborations in biopharmaceutical, tourism, and insurance-based areas. Long-term value is to be created through investments in research and development and projects in cooperation with local governments. Another growth boost comes from Fosun Pharma. Chen Qiyu reported significant progress in the introduction of innovative drugs such as Serplulimab to global markets. The expansion is supported by building distribution networks in the Middle East, Southeast Asia, and South America. Additionally, the capacity for clinical trials and registrations is being strengthened to further expand international market presence.